ALS Invest 1 B.V. 4
4 · Amylyx Pharmaceuticals, Inc. · Filed Jul 8, 2022
Insider Transaction Report
Form 4
ALS Invest 1 B.V.
10% Owner
Transactions
- Sale
Common Stock
2022-07-06$19.54/sh−18,312$357,816→ 5,937,577 total - Sale
Common Stock
2022-07-06$20.60/sh−10,395$214,137→ 5,927,182 total - Sale
Common Stock
2022-07-06$21.32/sh−29,595$630,965→ 5,897,587 total - Sale
Common Stock
2022-07-06$22.42/sh−2,307$51,723→ 5,895,280 total
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.975, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3), (4) and (5) to this Form 4.
- [F2]The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.99, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.00 to $21.73, inclusive.
- [F5]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.03 to $22.655, inclusive.